Brad L. Tade serves as the Chief Financial Officer and Treasurer at ADMA Biologics, Inc., a role he has held since joining the company in 2017. In this capacity, Tade oversees the financial operations and strategic planning for ADMA Biologics, which specializes in developing and commercializing plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. His leadership has been instrumental in guiding the company through significant growth phases, including the successful launch and scaling of key products such as BIVIGAM and ASCENIV. Prior to joining ADMA Biologics, Tade amassed over 25 years of experience in financial management and corporate strategy across various industries. He held several senior financial roles, including CFO positions at companies like Genesis HealthCare and CCS Medical. His tenure at these organizations was marked by his ability to drive financial performance, streamline operations, and enhance shareholder value. Tade's strategic foresight and financial acumen have been pivotal in his achievements, earning him a reputation as a respected leader in the financial domain. At ADMA Biologics, Tade's role extends beyond traditional CFO responsibilities; he is a key member of the executive team, contributing to the company's overall strategic direction. His efforts have been crucial in securing funding, managing investor relations, and navigating the complex regulatory landscape of the biopharmaceutical industry. Under his stewardship, ADMA Biologics has strengthened its financial position, enabling continued investment in research and development and the expansion of its product portfolio. Tade's dedication to the company's mission and his strategic leadership continue to drive ADMA Biologics toward its goal of improving the lives of patients with rare diseases.